Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.52 |
| ▸ | MMP2 | P08253 | 13/20 | 0.52 |
| ▸ | MMP3 | P08254 | 7/20 | 0.47 |
| ▸ | MMP9 | P14780 | 7/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457310 | 0.88 | ADAM10 (0.56) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3458128 | 0.85 | ADAM10 (0.52) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457777 | 0.84 | ADAM10 (0.51) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457143 | 0.81 | SIGMAR1 (0.51) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457901 | 0.81 | SIGMAR1 (0.51) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457135 | 0.81 | ADAM10 (0.47) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL4558713 | 0.81 | ADAM10 (0.47) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457263 | 0.81 | ADAM10 (0.49) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3457502 | 0.80 | ADAM10 (0.53) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL3458696 | 0.80 | ADAM10 (0.47) | ADAM10ERBB2MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | ADAM10 25/4885ERBB2 2986/4885MMP2 4/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.